Back to Articles
Pediatric Oncology

Overcoming Resistance in Targeted Therapy for NF1

Dr. Iana Dzhelieva
March 15, 2024
5 min read
Overcoming Resistance in Targeted Therapy for NF1

Abstract

Neurofibromatosis Type 1 (NF1) is a genetic disorder characterized by the development of benign and malignant tumors. The advent of MEK inhibitors like Selumetinib has transformed treatment, yet many patients eventually develop resistance. This article examines the molecular mechanisms behind this escape.

Introduction: The Ras Interface

The NF1 gene encodes neurofibromin, a protein that acts as a negative regulator of the Ras pathway. Loss of neurofibromin leads to hyperactive Ras, driving uncontrolled cell growth. Targeted therapies aim to "block the signal" downstream at the MEK level.

Analysis: Mechanisms of Escape

Why do responsive tumors suddenly stop shrinking?

1. Alternate Pathway Activation In some cases, the cell learns to bypass the MEK block by activating the PI3K/AKT/mTOR pathway, providing a different set of orders for cell division.

2. Secondary Mutations Genomic instability in tumors can lead to new mutations within the Ras protein itself, rendering the initial inhibitor ineffective.

3. The Microenvironment Tumor-associated fibroblasts and immune cells can secrete growth factors that shield the tumor cells from the effects of the drug.

Conclusion

The future of NF1 treatment lies in "combination therapy," targeting multiple nodes in the pathway simultaneously to prevent the cell from finding an alternative route to survival.

References

  1. Barker D, et al. (1987). Science.
  2. Cawthon R, et al. (1990). Cell.
  3. Chang T, et al. (2005). Journal of Clinical Oncology.
  4. Chantre-Justino M, et al. (2019). Oncology Reports.
  5. Dasgupta B, et al. (2003). Journal of Neuroscience Research.
  6. Dome J, et al. (2015). Pediatric Blood & Cancer.
  7. Dombi E, et al. (2016). New England Journal of Medicine.
  8. Evans D, et al. (1910). Journal of Medical Genetics.
  9. Gutmann D, et al. (2017). JAMA Neurology.
  10. Hanada S, et al. (2020). Journal of General Medicine.
  11. Jett K, et al. (2010). Genetics in Medicine.
  12. Kehrer-Sawatzki H, et al. (2012). Human Genetics.
  13. Kim A, et al. (2017). Journal of Clinical Oncology.
  14. Korf B. (1999). New England Journal of Medicine.
  15. Legius E, et al. (2021). Genetics in Medicine.
  16. Packer R, et al. (2017). Neuro-Oncology.
  17. Peltonen S, et al. (2017). Journal of Investigative Dermatology.
  18. Plotkin S, et al. (2013). Current Opinion in Neurology.
  19. Ratner N, et al. (2015). Nature Reviews Cancer.
  20. Widemann B, et al. (2014). Journal of Clinical Oncology.